{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:28:26Z","timestamp":1782995306814,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Social development projects of Yunnan Province","award":["202302AA310044"],"award-info":[{"award-number":["202302AA310044"]}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100018576","name":"Ten Thousand Talent Plans for Young Top-notch Talents of Yunnan Province","doi-asserted-by":"publisher","award":["2023-KHRCBZ-B08"],"award-info":[{"award-number":["2023-KHRCBZ-B08"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100018576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03618-x","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:02:13Z","timestamp":1701280933000},"page":"836-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of SGLT2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials"],"prefix":"10.1007","volume":"84","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zou-Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-8932","authenticated-orcid":false,"given":"Wei-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"10166","key":"3618_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31\u201339 (2019). https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"issue":"11","key":"3618_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"B.L. Neuen, T. Young, H. Heerspink, B. Neal, V. Perkovic, L. Billot et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endo. 7(11), 845\u2013854 (2019). https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endo."},{"issue":"10254","key":"3618_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"F. Zannad, J.P. Ferreira, S.J. Pocock, S.D. Anker, J. Butler, G. Filippatos et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the emperor-reduced and dapa-hf trials. Lancet 396(10254), 819\u2013829 (2020). https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"issue":"10354","key":"3618_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"M. Vaduganathan, K.F. Docherty, B.L. Claggett, P.S. Jhund, R.A. de Boer, A.F. Hernandez et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354), 757\u2013767 (2022). https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"key":"3618_CR5","doi-asserted-by":"publisher","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365), 1788\u20131801 (2022). https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"3618_CR6","doi-asserted-by":"publisher","first-page":"724405","DOI":"10.3389\/fphar.2021.724405","volume":"12","author":"DG Yin","year":"2021","unstructured":"D.G. Yin, M. Qiu, X.Y. Duan, Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. Front. Pharmacol. 12, 724405 (2021). https:\/\/doi.org\/10.3389\/fphar.2021.724405","journal-title":"Front. Pharmacol."},{"issue":"5","key":"3618_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/FJC.0000000000001222","volume":"79","author":"HT Zou","year":"2022","unstructured":"H.T. Zou, G.H. Yang, Y.J. Cai, H. Chen, X.Q. Zheng, R. Hu, Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis. J. Cardiovasc. Pharm. 79(5), 655\u2013662 (2022). https:\/\/doi.org\/10.1097\/FJC.0000000000001222","journal-title":"J. Cardiovasc. Pharm."},{"issue":"5","key":"3618_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jcpt.13588","volume":"47","author":"XX Liao","year":"2022","unstructured":"X.X. Liao, W.Q. Li, Z.K. Peng, H.B. Yu, J. Tan, Three new categories of hypoglycaemic agents and various cardiovascular diseases: a meta-analysis. J. Clin. Pharm. Ther. 47(5), 636\u2013642 (2022). https:\/\/doi.org\/10.1111\/jcpt.13588","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"3618_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"W.G. Herrington, N. Staplin, C. Wanner, J.B. Green, S.J. Hauske, J.R. Emberson et al. Empagliflozin in patients with chronic kidney disease. N. Engl J. Med. 388(2), 117\u2013127 (2023). https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N. Engl J. Med."},{"issue":"16","key":"3618_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. B\u00f6hm et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl J. Med. 385(16), 1451\u20131461 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N. Engl J. Med."},{"issue":"12","key":"3618_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"S.D. Solomon, J. McMurray, B. Claggett, R.A. de Boer, D. DeMets, A.F. Hernandez et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl J. Med. 387(12), 1089\u20131098 (2022). https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N. Engl J. Med."},{"issue":"2","key":"3618_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"D.L. Bhatt, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl J. Med. 384(2), 117\u2013128 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N. Engl J. Med."},{"issue":"2","key":"3618_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"D.L. Bhatt, M. Szarek, B. Pitt, C.P. Cannon, L.A. Leiter, D.K. McGuire et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl J. Med. 384(2), 129\u2013139 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N. Engl J. Med."},{"issue":"3","key":"3618_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"D. Li, T. Wang, S. Shen, Z. Fang, Y. Dong, H. Tang, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 19(3), 348\u2013355 (2017). https:\/\/doi.org\/10.1111\/dom.12825","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"3618_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"R. Puckrin, M.P. Saltiel, P. Reynier, L. Azoulay, O. Yu, K.B. Filion, SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55(5), 503\u2013514 (2018). https:\/\/doi.org\/10.1007\/s00592-018-1116-0","journal-title":"Acta Diabetol."},{"issue":"2","key":"3618_CR16","doi-asserted-by":"publisher","first-page":"1476853704","DOI":"10.1177\/14791641211011016","volume":"18","author":"M Qiu","year":"2021","unstructured":"M. Qiu, L.L. Ding, M. Zhang, H.R. Zhou, Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors. Diab. Vasc. Dis. Res. 18(2), 1476853704 (2021). https:\/\/doi.org\/10.1177\/14791641211011016","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"7","key":"3618_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS Lin","year":"2021","unstructured":"D.S. Lin, J.K. Lee, W.J. Chen, Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J. Clin. Endocr. Metab. 106(7), 2133\u20132145 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab274","journal-title":"J. Clin. Endocr. Metab."},{"key":"3618_CR18","doi-asserted-by":"publisher","first-page":"1238399","DOI":"10.3389\/fendo.2023.1238399","volume":"14","author":"CX Li","year":"2023","unstructured":"C.X. Li, L.Y. Liu, C.X. Zhang, X.H. Geng, S.M. Gu, Y.Q. Wang et al. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front. Endocrinol. 14, 1238399 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1238399","journal-title":"Front. Endocrinol."},{"issue":"7","key":"3618_CR19","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 6(7), e1000097 (2009). https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med."},{"key":"3618_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"J.P. Higgins, D.G. Altman, P.C. G\u00f8tzsche, P. J\u00fcni, D. Moher, A.D. Oxman et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 343, d5928 (2011). https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ."},{"issue":"15","key":"3618_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"H Heerspink","year":"2020","unstructured":"H. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter, G.M. Chertow, T. Greene, F.F. Hou et al. Dapagliflozin in patients with chronic kidney disease. N. Engl J. Med. 383(15), 1436\u20131446 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N. Engl J. Med."},{"issue":"15","key":"3618_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"M. Packer, S.D. Anker, J. Butler, G. Filippatos, S.J. Pocock, P. Carson et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl J. Med. 383(15), 1413\u20131424 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N. Engl J. Med."},{"issue":"21","key":"3618_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"J McMurray","year":"2019","unstructured":"J. McMurray, S.D. Solomon, S.E. Inzucchi, L. Kober, M.N. Kosiborod, F.A. Martinez et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl J. Med. 381(21), 1995\u20132008 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N. Engl J. Med."},{"issue":"7","key":"3618_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"B. Neal, V. Perkovic, K.W. Mahaffey, D. de Zeeuw, G. Fulcher, N. Erondu et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl J. Med. 377(7), 644\u2013657 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N. Engl J. Med."},{"issue":"24","key":"3618_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"V. Perkovic, M.J. Jardine, B. Neal, S. Bompoint, H. Heerspink, D.M. Charytan et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl J. Med. 380(24), 2295\u20132306 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N. Engl J. Med."},{"key":"3618_CR26","doi-asserted-by":"publisher","unstructured":"C.P. Cannon, R. Pratley, S. Dagogo-Jack, J. Mancuso, S. Huyck, U. Masiukiewicz et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl J. Med. (2020). https:\/\/doi.org\/10.1056\/NEJMoa2004967","DOI":"10.1056\/NEJMoa2004967"},{"issue":"4","key":"3618_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl J. Med. 380(4), 347\u2013357 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N. Engl J. Med."},{"issue":"22","key":"3618_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl J. Med. 373(22), 2117\u20132128 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N. Engl J. Med."},{"key":"3618_CR29","doi-asserted-by":"publisher","unstructured":"S. James, D. Erlinge, R.F. Storey, D.K. McGuire, M. de Belder, I. Bj\u00f6rkgren et al. Rationale and design of the DAPA-MI trial: dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Am. Heart J. 266, 188\u2013197 (2023). https:\/\/doi.org\/10.1016\/j.ahj.2023.08.008","DOI":"10.1016\/j.ahj.2023.08.008"},{"key":"3618_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","volume":"253","author":"J Harrington","year":"2022","unstructured":"J. Harrington, J.A. Udell, W.S. Jones, S.D. Anker, D.L. Bhatt, M.C. Petrie et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am. Heart J. 253, 86\u201398 (2022). https:\/\/doi.org\/10.1016\/j.ahj.2022.05.010","journal-title":"Am. Heart J."},{"key":"3618_CR31","doi-asserted-by":"publisher","unstructured":"B.M. Mishriky, D.M. Cummings, J.R. Powell, A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-is there a true benefit? Diabetes Metab. Res. Rev. e3715 (2023). https:\/\/doi.org\/10.1002\/dmrr.3715","DOI":"10.1002\/dmrr.3715"},{"issue":"2","key":"3618_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"A.M. Fawzy, J.M. Rivera-Caravaca, P. Underhill, L. Fauchier, G. Lip, Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database. Diabetes Obes. Metab. 25(2), 602\u2013610 (2023). https:\/\/doi.org\/10.1111\/dom.14854","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"3618_CR33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"G.D. Lopaschuk, S. Verma, Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl. Sci. 5(6), 632\u2013644 (2020). https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004","journal-title":"JACC Basic Transl. Sci."},{"issue":"11","key":"3618_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.medj.2021.10.004","volume":"2","author":"D Cherney","year":"2021","unstructured":"D. Cherney, J.A. Udell, D.J. Drucker, Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med. 2(11), 1203\u20131230 (2021). https:\/\/doi.org\/10.1016\/j.medj.2021.10.004","journal-title":"Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03618-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:26:40Z","timestamp":1719386800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03618-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03618-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"24 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}